CONTINUE TO SITE >

OR WAIT 15 SECS

AMCPAutoimmune DiseasesBiosimilarsCardiovascular DiseasesEyecareHow to Reduce Maternal, Infant Health Risks During COVID-19Improving Ophthalmic Care Access and Treatment Among Aging AdultsMultiple SclerosisSecondary Progressive Multiple Sclerosis: Patient Impact and Coverage Implications for New Therapies

Business

Business StrategyConsumersDrug CostsDrug PipelineFormularyHealth ManagementHealth/Disease StrategyHospitals & ProvidersIndustry AnalysisPharmacyPolitics and PolicyPractice ManagementReimbursementTechnology

Clinical

Autoimmune DiseasesBiosimilarsDermatologyDiabetesEyecareLeukemia and LymphomaMental HealthObstetrics-Gynecology & Women's HealthOncologyOpioidsPediatricsPlaque PsoriasisSolid TumorsUrology

News

Media

Expert InterviewsK-CastMedical World NewsPodcasts

Conferences

Publications

Resources

AstraZeneca's Adrian Kilcoyne Discusses Small Lung Cancer (pt.2)

June 7, 2020

Mary Caffrey

Conferences | ASCO

Adrian Kilcoyne MD MBA MPH, vice president, US Medical Affairs and HEOR, oncology, AstraZeneca, discusses small lung cancer and the presentation he held at the annual ASCO20 meeting in late May.